Imagine...

At Patient Testing (APT) in 30 Minutes.

Our innovative Genetic Discovery Technology (GDT) based on real-time qPCR is capable of amplifying RNA and DNA targets direct from crude samples in under 30 minutes ...At Patient Testing (APT) is now a reality

Helping to significantly improve global health outcomes – but most importantly, save lives.

At Patient Testing

Our platform technology allows anyone to carry out RT-qPCR diagnostic testing direct from crude samples (including whole blood) anywhere in the world without the need for specialist training, facilities or equipment whilst the patient waits in under 30 minutes.

Discover APT

CENOS represents a paradigm shift in current molecular diagnostics - the first line of defence in conjunction with RT-qPCR lab based testing (for high throughput and sensitivity screening focused on population health), Lateral Flow Testing (for mass population screening) and vaccination programmes as part of a holistic and multi-faceted strategy to effectively combat High Consequence Infectious Diseases (HCID).

Discover Cenos

Pandemic Preparedness

There is no single magic bullet to end pandemics, but there is a combination of measures that will - commitment, finance, global public goods, alerts and preparedness, and leadership. With so many lives at stake, now is the time for resolve.

Our Work & Stakeholders

At BioGene we focus on High Consequence Infectious Diseases (HCID). This involves targeting both neglected diseases and Emerging Infectious Diseases (EIDs). Our key stakeholders include healthcare professionals for rapid response to outbreaks of emerging diseases and we develop diagnostic tests not just for human IVD applications but also in-field/penside veterinary testing.